Stock Analyses

Model-driven valuations for thousands of US-listed stocks, built from SEC EDGAR filings. Click any card to see the full analysis.

All sectors 6,479 Financial Services 1,900 Healthcare 1,116 Technology 1,079 Industrials 668 Consumer Cyclical 490 Basic Materials 337 Consumer Defensive 248 Communication Services 213 Utilities 183 Energy 165 Real Estate 80

1,116 stocks · page 6 of 19

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Contineum Therapeutics, Inc.

Market implies +18.4%/yr vs model +15.0% · above model

CITIUS ONCOLOGY, INC.

Cytosorbents Corp

Market implies +37.5%/yr vs model +2.0% · above model

Citius Pharmaceuticals, Inc.

Market implies +67.7%/yr vs model +15.0% · above model

Cue Biopharma, Inc.

Market implies +92.7%/yr vs model +16.4% · above model

Cuprina Holdings (Cayman) LTD

Market implies +70.0%/yr vs model +15.0% · above model

Curanex Pharmaceuticals Inc

CapsoVision, Inc

Market implies +19.1%/yr vs model +15.3% · above model

Cadrenal Therapeutics, Inc.

Deeply undervalued

Discount 73% Return to IV: +267.2%

Market implies -24.4%/yr vs model +44.4% · below model

Cyclerion Therapeutics, Inc.

Market implies +106.6%/yr vs model +2.0% · above model

Market implies +93.8%/yr vs model +15.0% · above model

COMMUNITY HEALTH SYSTEMS INC

Market implies -27.7%/yr vs model +3.2% · below model

CYPHERPUNK TECHNOLOGIES INC.

Market implies +74.8%/yr vs model +15.0% · above model

Market implies +47.6%/yr vs model +2.0% · above model

CYTOKINETICS INC

Deeply undervalued

Model IV$1,068.82

Discount 93% Return to IV: +1,348.9%

Market implies -50.0%/yr vs model +5.7% · below model

Deeply overvalued

Premium +42% Return to IV: -29.3%

Market implies -3.5%/yr vs model +2.0% · below model

Dare Bioscience, Inc.

Market implies +7.4%/yr vs model +15.0% · below model

DBV Technologies S.A.

Market implies +93.1%/yr vs model +2.0% · above model

Deeply undervalued

Discount 66% Return to IV: +191.9%

Owner yield 23.5% 10-yr IRR 33.5% · steady

Market implies -18.8%/yr vs model +3.2% · below model

Decoy Therapeutics Inc.

DELCATH SYSTEMS, INC.

Premium +28% Return to IV: -21.9%

Market implies +5.0%/yr vs model +50.0% · below model

Journey Medical Corp

Premium +43% Return to IV: -30.0%

Market implies +2.2%/yr vs model +5.5% · below model

Definium Therapeutics, Inc.

QUEST DIAGNOSTICS INC

Deeply undervalued

Model IV$352.30

Discount 30% Return to IV: +42.9%

Owner yield 3.8% 10-yr IRR 4.6% · moderate

Market implies +1.0%/yr vs model +6.5% · below model

DANAHER CORP /DE/

Deeply overvalued

Model IV$130.15

Premium +63% Return to IV: -38.6%

Owner yield 3.6% 10-yr IRR 2.1% · steady

Market implies +9.6%/yr vs model +3.7% · above model

DiaMedica Therapeutics Inc.

Damora Therapeutics, Inc.

Ginkgo Bioworks Holdings, Inc.

Market implies +54.2%/yr vs model +2.0% · above model

Denali Therapeutics Inc.

Market implies +33.7%/yr vs model +15.0% · above model

Dianthus Therapeutics, Inc. /DE/

Market implies +116.9%/yr vs model +15.0% · above model

DarioHealth Corp.

Discount 9% Return to IV: +9.8%

Market implies -10.4%/yr vs model +2.2% · below model

Dermata Therapeutics, Inc.

Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd.

BRIGHT MINDS BIOSCIENCES INC.

Design Therapeutics, Inc.

PRECISION BIOSCIENCES INC

Market implies +24.1%/yr vs model +2.0% · above model

Deeply undervalued

Model IV$590.72

Discount 69% Return to IV: +221.3%

Owner yield 10.2% 10-yr IRR 22.3% · moderate

Market implies -6.4%/yr vs model +9.9% · below model

Dogwood Therapeutics, Inc.

Premium +16% Return to IV: -14.0%

Owner yield 2.0% 10-yr IRR 3.1% · grower

Market implies +14.7%/yr vs model +16.6% · in line

DYADIC INTERNATIONAL INC

Market implies +20.3%/yr vs model +6.5% · above model

Dyne Therapeutics, Inc.

Emergent BioSolutions Inc.

Deeply undervalued

Discount 71% Return to IV: +250.1%

Market implies -21.2%/yr vs model +2.0% · below model

electroCore, Inc.

Premium +53% Return to IV: -34.6%

Market implies -0.8%/yr vs model +15.0% · below model

Editas Medicine, Inc.

Market implies +46.4%/yr vs model +12.2% · above model

Edesa Biotech, Inc.

Encompass Health Corp

Model IV$134.43

Discount 9% Return to IV: +10.2%

Owner yield 2.9% 10-yr IRR 3.9% · moderate

Market implies +6.8%/yr vs model +10.2% · below model

Eikon Therapeutics, Inc.

PMGC Holdings Inc.

Deeply overvalued

Premium +129% Return to IV: -56.3%

Elanco Animal Health Inc

Deeply overvalued

Premium +362% Return to IV: -78.4%

Owner yield 2.3% 10-yr IRR -3.4% · steady

Market implies +24.4%/yr vs model +3.0% · above model

Eledon Pharmaceuticals, Inc.

Electromed, Inc.

Deeply overvalued

Premium +11% Return to IV: -10.1%

Owner yield 2.7% 10-yr IRR 5.8% · grower

Market implies +11.8%/yr vs model +14.0% · in line

ELECTRO SENSORS INC

Deeply overvalued

Premium +98% Return to IV: -49.5%

Owner yield 1.2% 10-yr IRR -9.1% · steady

Market implies +9.8%/yr vs model +5.9% · above model

Elicio Therapeutics, Inc.

Market implies +34.0%/yr vs model +15.0% · above model

Deeply overvalued

Premium +132% Return to IV: -57.0%

Market implies +2.0%/yr vs model +2.0% · in line

Enliven Therapeutics, Inc.

Deeply undervalued

Discount 86% Return to IV: +600.5%

Owner yield 27.9% 10-yr IRR 37.9% · steady

Market implies -30.4%/yr vs model +3.0% · below model